Crispr Therapeutics AG Insider Trading

CRSP

Last 12 months

Insiders sold $17.9M and bought nothing on the open market.

62% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Samarth Kulkarni sold $2.38M on Oct 19, 13% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$17.9M

0 buys · 23 sales

Under a 10b5-1 plan

62%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Aug 2025

Aug 6, 2025

Get an email when CRSP's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 19	Samarth Kulkarni Chief Executive Officer	SoldNo plan	47,837	$49.78	$2.38M	13%	Form 4
Oct 14	Simeon George Director	Sold10b5-1 plan	14,514	$49.63	720K	0.7%	Form 4
Oct 14	James R. Kasinger General Counsel and Secretary	SoldNo plan	1,040	$49.26	51K	1.1%	Form 4
Oct 14	Samarth Kulkarni Chief Executive Officer	SoldNo plan	4,098	$49.26	202K	1.6%	Form 4
Oct 6	James R. Kasinger General Counsel and Secretary	Sold10b5-1 plan	1,990	$60.04	119K	2.1%	Form 4
Sep 22	James R. Kasinger General Counsel and Secretary	Sold10b5-1 plan	10,400	$60.24	626K	9.9%	Form 4
Sep 17	Ali Behbahani Director	SoldNo plan	13,679	$57.09	781K	45%	Form 4
May 29	Naimish Patel Chief Medical Officer	SoldNo plan	3,786	$55.62	211K	16%	Form 4
Mar 23	James R. Kasinger General Counsel and Secretary	SoldNo plan	3,182	$46.78	149K	3.3%	Form 4
Mar 23	Samarth Kulkarni Chief Executive Officer	SoldNo plan	10,020	$46.78	469K	3.8%	Form 4
Mar 23	Raju Prasad Chief Financial Officer	SoldNo plan	3,708	$46.78	173K	19%	Form 4
Mar 16	Naimish Patel Chief Medical Officer	SoldNo plan	3,150	$48.26	152K	19%	Form 4
Mar 16	Raju Prasad Chief Financial Officer	SoldNo plan 2 parts	9,869	$48.26 average	476K	43%	Form 4
Mar 16	James R. Kasinger General Counsel and Secretary	SoldNo plan	3,450	$48.26	166K	3.6%	Form 4
Mar 16	Samarth Kulkarni Chief Executive Officer	SoldNo plan	10,349	$48.26	499K	4.0%	Form 4
Mar 11	James R. Kasinger General Counsel and Secretary	SoldNo plan	2,800	$52.80	148K	3.1%	Form 4
Mar 11	Samarth Kulkarni Chief Executive Officer	SoldNo plan	9,798	$52.80	517K	4.0%	Form 4
Feb 19	Samarth Kulkarni Chief Executive Officer	SoldNo plan	6,967	$52.58	366K	3.0%	Form 4
Feb 19	James R. Kasinger General Counsel and Secretary	SoldNo plan	2,112	$52.58	111K	2.4%	Form 4
Jan 22	Raju Prasad Chief Financial Officer	Sold10b5-1 plan	34,972	$60.19	$2.1M	84%	Form 4
Jan 20 – 22	Samarth Kulkarni Chief Executive Officer	Sold10b5-1 plan 3 parts	90,000	$57.40 average	$5.17M	29%	Form 4
Jan 6	Raju Prasad Chief Financial Officer	Sold10b5-1 plan 3 parts	29,700	$60.16 average	$1.79M	81%	Form 4
Dec 22, 2025	Raju Prasad Chief Financial Officer	Sold10b5-1 plan 3 parts	10,000	$55.95 average	560K	60%	Form 4
Oct 17, 2025	Samarth Kulkarni Chief Executive Officer	SoldNo plan	50,895	$67.91	$3.46M	13%	Form 4
Oct 14, 2025	Samarth Kulkarni Chief Executive Officer	SoldNo plan	4,242	$66.60	283K	1.4%	Form 4
Oct 14, 2025	James R. Kasinger General Counsel and Secretary	SoldNo plan	1,076	$66.60	72K	1.3%	Form 4
Aug 18, 2025	Samarth Kulkarni Chief Executive Officer	SoldNo plan	13,081	$58.15	761K	4.3%	Form 4
Aug 6, 2025	Douglas A Treco Director	Bought	20,000	$57.03	$1.14M	1000%	Form 4
Jul 16, 2025	Simeon George Director	Bought 3 parts	989,812	$52.03 average	$51.5M	94%	Form 4
May 29, 2025	Naimish Patel Chief Medical Officer	SoldNo plan	3,932	$35.94	141K	39%	Form 4
Apr 3, 2025	Naimish Patel Chief Medical Officer	Bought	1,508	$32.96	50K	New	Form 4
Mar 21, 2025	Samarth Kulkarni Chief Executive Officer	SoldNo plan	10,031	$41.23	414K	3.5%	Form 4
Mar 21, 2025	Julianne Bruno Chief Operating Officer	SoldNo plan	1,714	$41.23	71K	8.9%	Form 4
Mar 21, 2025	Raju Prasad Chief Financial Officer	SoldNo plan	2,197	$41.23	91K	12%	Form 4
Mar 21, 2025	James R. Kasinger General Counsel and Secretary	SoldNo plan	3,185	$41.23	131K	3.8%	Form 4
Mar 17, 2025	Raju Prasad Chief Financial Officer	SoldNo plan	3,762	$41.80	157K	23%	Form 4
Mar 11, 2025 – Mar 12, 2025	Samarth Kulkarni Chief Executive Officer	SoldNo plan 2 parts	14,435	$42.70 average	616K	5.1%	Form 4
Mar 11, 2025 – Mar 12, 2025	James R. Kasinger General Counsel and Secretary	SoldNo plan 2 parts	3,966	$42.67 average	169K	4.8%	Form 4
Mar 11, 2025 – Mar 12, 2025	Julianne Bruno Chief Operating Officer	SoldNo plan 2 parts	1,388	$42.54 average	59K	8.2%	Form 4
Feb 26, 2025	John Greene Director	Bought	7,000	$44.85	314K	New	Form 4

Oct 19No plan
Samarth Kulkarni
Chief Executive Officer · sold 47,837 at $49.78
$2.38M
13% of stake
Oct 1410b5-1 plan
Simeon George
Director · sold 14,514 at $49.63
720K
0.7% of stake
Oct 14No plan
James R. Kasinger
General Counsel and Secretary · sold 1,040 at $49.26
51K
1.1% of stake
Oct 14No plan
Samarth Kulkarni
Chief Executive Officer · sold 4,098 at $49.26
202K
1.6% of stake
Oct 610b5-1 plan
James R. Kasinger
General Counsel and Secretary · sold 1,990 at $60.04
119K
2.1% of stake
Sep 2210b5-1 plan
James R. Kasinger
General Counsel and Secretary · sold 10,400 at $60.24
626K
9.9% of stake
Sep 17No plan
Ali Behbahani
Director · sold 13,679 at $57.09
781K
45% of stake
May 29No plan
Naimish Patel
Chief Medical Officer · sold 3,786 at $55.62
211K
16% of stake
Mar 23No plan
James R. Kasinger
General Counsel and Secretary · sold 3,182 at $46.78
149K
3.3% of stake
Mar 23No plan
Samarth Kulkarni
Chief Executive Officer · sold 10,020 at $46.78
469K
3.8% of stake
Mar 23No plan
Raju Prasad
Chief Financial Officer · sold 3,708 at $46.78
173K
19% of stake
Mar 16No plan
Naimish Patel
Chief Medical Officer · sold 3,150 at $48.26
152K
19% of stake
Mar 16No plan
Raju Prasad
Chief Financial Officer · sold 9,869 at avg $48.26
476K
43% of stake
Mar 16No plan
James R. Kasinger
General Counsel and Secretary · sold 3,450 at $48.26
166K
3.6% of stake
Mar 16No plan
Samarth Kulkarni
Chief Executive Officer · sold 10,349 at $48.26
499K
4.0% of stake
Mar 11No plan
James R. Kasinger
General Counsel and Secretary · sold 2,800 at $52.80
148K
3.1% of stake
Mar 11No plan
Samarth Kulkarni
Chief Executive Officer · sold 9,798 at $52.80
517K
4.0% of stake
Feb 19No plan
Samarth Kulkarni
Chief Executive Officer · sold 6,967 at $52.58
366K
3.0% of stake
Feb 19No plan
James R. Kasinger
General Counsel and Secretary · sold 2,112 at $52.58
111K
2.4% of stake
Jan 2210b5-1 plan
Raju Prasad
Chief Financial Officer · sold 34,972 at $60.19
$2.1M
84% of stake
Jan 20 – 2210b5-1 plan
Samarth Kulkarni
Chief Executive Officer · sold 90,000 at avg $57.40
$5.17M
29% of stake
Jan 610b5-1 plan
Raju Prasad
Chief Financial Officer · sold 29,700 at avg $60.16
$1.79M
81% of stake
Dec 22, 202510b5-1 plan
Raju Prasad
Chief Financial Officer · sold 10,000 at avg $55.95
560K
60% of stake
Oct 17, 2025No plan
Samarth Kulkarni
Chief Executive Officer · sold 50,895 at $67.91
$3.46M
13% of stake
Oct 14, 2025No plan
Samarth Kulkarni
Chief Executive Officer · sold 4,242 at $66.60
283K
1.4% of stake
Oct 14, 2025No plan
James R. Kasinger
General Counsel and Secretary · sold 1,076 at $66.60
72K
1.3% of stake
Aug 18, 2025No plan
Samarth Kulkarni
Chief Executive Officer · sold 13,081 at $58.15
761K
4.3% of stake
Aug 6, 2025
Douglas A Treco
Director · bought 20,000 at $57.03
$1.14M
1000% of stake
Jul 16, 2025
Simeon George
Director · bought 989,812 at avg $52.03
$51.5M
94% of stake
May 29, 2025No plan
Naimish Patel
Chief Medical Officer · sold 3,932 at $35.94
141K
39% of stake
Apr 3, 2025
Naimish Patel
Chief Medical Officer · bought 1,508 at $32.96
50K
New position
Mar 21, 2025No plan
Samarth Kulkarni
Chief Executive Officer · sold 10,031 at $41.23
414K
3.5% of stake
Mar 21, 2025No plan
Julianne Bruno
Chief Operating Officer · sold 1,714 at $41.23
71K
8.9% of stake
Mar 21, 2025No plan
Raju Prasad
Chief Financial Officer · sold 2,197 at $41.23
91K
12% of stake
Mar 21, 2025No plan
James R. Kasinger
General Counsel and Secretary · sold 3,185 at $41.23
131K
3.8% of stake
Mar 17, 2025No plan
Raju Prasad
Chief Financial Officer · sold 3,762 at $41.80
157K
23% of stake
Mar 11, 2025 – Mar 12, 2025No plan
Samarth Kulkarni
Chief Executive Officer · sold 14,435 at avg $42.70
616K
5.1% of stake
Mar 11, 2025 – Mar 12, 2025No plan
James R. Kasinger
General Counsel and Secretary · sold 3,966 at avg $42.67
169K
4.8% of stake
Mar 11, 2025 – Mar 12, 2025No plan
Julianne Bruno
Chief Operating Officer · sold 1,388 at avg $42.54
59K
8.2% of stake
Feb 26, 2025
John Greene
Director · bought 7,000 at $44.85
314K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CRSP, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CRSP

CompareIntrinsic value

MGXMetagenomi, Inc.

$0.79+3.95%10

ACLXArcellx, Inc.

No recent price10

GLUEMonte Rosa Therapeutics, Inc.

$10.82+3.94%10

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

SCLXScilex Holding Company

$1.83-1.08%0

VYGRVoyager Therapeutics Inc.

$1.87+2.19%10

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

Held by ETFs

CRSP is in 67 US ETFs. The largest of them, with CRSP's weight in each:

Spot a number that looks wrong? Check it in CRSP's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CRSP

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.